5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. - Wikidata - wikimedia - TriplyDB

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

http://www.wikidata.org/entity/Q37678414

about

Novel immunotherapy in metastatic renal cell carcinoma.The immune response to tumors as a tool toward immunotherapy.The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy.Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Nanoparticle delivery systems in cancer vaccines.Oncolytic vaccinia virus for the treatment of cancer.Colorectal cancer vaccines in clinical trials.Prostate cancer vaccines.Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.

P2860

Q33863074-1C4151D2-A06C-4204-B6F8-100946F55EAA Q34634545-F73DC879-20B9-430E-87AB-50984E867951 Q34808155-D8D92F35-2325-4F94-825F-AC2468560F56 Q34995286-14C7D75A-BDA8-4859-BF79-AD0869FD0136 Q35174485-04B31DEE-E581-42FF-A21B-70C200D1F535 Q35571248-C1DEEB6C-F840-456A-BD74-431D2963EE32 Q35677112-35FDF795-7E69-467B-871F-C940DCD002EB Q36574571-57D55DDE-5E5E-4A48-A15D-35342FC33089 Q37845399-A9A3A2FA-73A4-4069-B7B9-A35237002249 Q37892600-222F8708-D7F7-4898-985C-32632343E4E2 Q38089935-E6008AA6-E036-42B8-92D0-085455B73EFD Q38248440-01A0B68D-94C7-4F73-B868-1A72B18B21D5

P2860

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

http://www.wikidata.org/entity/Q37678414

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

@en

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

@nl

type

label

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

@en

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

@nl

prefLabel

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

@en

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

@nl

P1433

Q37678414-343AE493-3F52-4726-AAC8-5F18518D059E

P1476

Q37678414-181DAA62-262D-44CA-B4B9-FC837060E895

P2093

Q37678414-E96848B3-D943-4BF8-8496-6D28DE93993C

P2860

Q37678414-001EA32D-30C9-4769-96F8-458A777F8A05

Q37678414-095DFAC6-2DB2-4287-A052-B317ECCF3423

Q37678414-0BFFFB5B-ED90-41E3-B50B-0E437D4FD6FD

Q37678414-2779E812-69DD-4C44-BADF-231D078155A6

Q37678414-2BB5E0AD-F9FC-423A-9F91-7D8BF1649C5E

Q37678414-33A9F247-8F99-4A38-8AAA-C847822E878B

Q37678414-41BE06EA-3AAF-449D-B7C8-67211D4DC12B

Q37678414-499D8A37-F849-4E37-8DD6-3DD56E2E5FDA

Q37678414-63618AD0-12A5-451F-9236-505FB01E94CC

Q37678414-71674629-103F-481B-B38D-F61F3536D51A

P304

Q37678414-3814F02F-D7AD-4636-A47D-38D25616B149

P31

Q37678414-D5AFB42D-4387-4337-9ABA-1BCD24994374

P356

Q37678414-8C8028A1-2C2A-4A4F-9B72-DB00383B2333

P407

Q37678414-8506E940-42A5-4985-8210-9288FE90AF09

P433

Q37678414-747806AA-E811-45BC-BB7F-00982215405A

P478

Q37678414-80ECDA4D-122A-4ED2-846D-59AFB79F4D1F

P577

Q37678414-503B7B9A-7905-43EA-8571-5801FDCB76F6

P698

Q37678414-ECD95EF1-EBEB-4CDF-B2FB-BB7FDB09188A

P921

Q37678414-A677CD27-7ACB-4110-BA9B-FE07C7D1AEC1

P356

14712590903586213

P1433

Expert Opinion on Biological Therapy

P1476

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

@en

P2093

Robert J Amato

http://www.w3.org/2001/XMLSchema#string

P2860

Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells.

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.

Immunohistological distribution of 5T4 antigen in normal and malignant tissues

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.

Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

P304

281-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712590903586213

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20088718

http://www.w3.org/2001/XMLSchema#string

P921